Eribulin may significantly improve overall survival (OS) and progression-free survival (PFS) compared with dacarbazine in patients with advanced liposarcoma (LPS) who have received prior therapies, according to a study published in The Journal of Clinical Oncology.
A previously conducted phase 3 study demonstrated that eribulin was superior to dacarbazine in improving OS in patients with LPS or leiomyosarcoma. For this histology-driven subgroup analysis, researchers investigated the effect of eribulin vs dacarbazine in patients with LPS.
Researchers randomly assigned 143 patients with LPS to receive eribulin or dacarbazine. Eligible patients had advanced or metastatic dedifferentiated, myxoid/round cell or pleomorphic LPS incurable by surgery or radiotherapy. Patients also needed to have undergone 2 or more prior systemic treatments, including one with anthracycline.
Overall survival in patients with LPS was significantly improved with eribulin vs dacarbazine: 15.6 months vs 8.4 months (hazard radio [HR], 0.51; 95% CI, 0.35-0.75; P <.001). Regardless of histologic subtype, overall survival was prolonged in all patients with LPS. In addition, progression-free survival was prolonged in the eribulin arm vs the dacarbazine arm (2.9 months vs 1.7 months; HR, 0.52; 95% CI, 0.35-0.78; P =.0015).
The safety profile was comparable in both arms.
The authors concluded that “eribulin represents an important treatment option for patients with LPS, a sarcoma subtype for which limited effective systemic treatments are available. Further studies are justified to explore the role of eribulin in earlier lines of therapy as well as in combination with other agents.”
1. Demetri GD, Schoffski P, Grignani G, et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine [published online August 30, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.71.6605